<DOC>
	<DOCNO>NCT01760187</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , single ascend dose ( SAD ) multiple ascend dose ( MAD ) study orally administer lomitapide healthy male Japanese Caucasian subject elevate LDL-C . The purpose study evaluate PK PD lomitapide Japanese subject compare Caucasian subject .</brief_summary>
	<brief_title>Phase I Study Safety , Tolerability , PK &amp; PD Lomitapide Japanese Caucasian Subjects With Elevated LDL-C</brief_title>
	<detailed_description />
	<criteria>1 . Subject healthy male Caucasian Japanese , age 20 45 year , inclusive , screen . 2 . Subject BMI 18.5 30 kg/m2 inclusive screening . 3 . Subjects must screen LDLC measurement mean Day 5 Day 6 measurement great equal 120mg/dL . 4 . Subjects must agree use acceptable method contraception ( detail provide protocol ) 5 . Subjects must capable understand comply requirement protocol must sign informed consent form prior undergoing studyrelated procedure . 1 . Subject clinically significant disease condition disease might affect drug absorption , distribution excretion . 2 . Any clinically significant abnormal laboratory , vital sign safety finding determine medical history , physical examination evaluation conduct screen admission . 3 . Electrocardiogram ( ECG ) abnormalities standard 12lead ECG ( screen ) opinion Investigator clinically relevant interfere ECG analysis . 4 . History current evidence clinically relevant cardiovascular , pulmonary , hepatic , renal , gastrointestinal , haematological , endocrinological , metabolic , neurological , psychiatric disease . 5 . Positive result serology test Hepatitis B Surface Antigen ( HbsAg ) , antiHepatitis core antibody ( antiHBc Ig G [ antiHBc IgM IgG positive ] , Hepatitis C antibody ( antiHCV ) , HIV 1 2 antibody , ( antiHIV 1/2 ) . 6 . Confirmed positive result urine drug screen alcohol breath test screen admission ( Day 1 ) . 7 . History clinical evidence alcohol drug abuse . 8 . Mentally handicap . 9 . Participation drug trial within 90 day prior first drug administration . 10 . Use medication ( include overthecounter ( OTC ) medication ) within 2 week prior admission ( Day 1 ) within less 10 time elimination halflife respective drug , anticipate concomitant medication treatment period . 11 . Use substance inhibit CYP3A4 enzyme within 2 week prior admission ( Day 1 ) . 12 . Donation 500 mL blood within 90 day prior drug administration . 13 . Subjects smoke 10 cigarette equivalent amount tobacco per day and/or stop smoking duration study whilst CPU . 14 . Treatment herbal supplement 7 day prior dose , use vitamin 48 hour prior admission ( Day 1 ) . 15 . Any circumstance condition , , opinion PI , may affect full participation trial compliance protocol . 16 . Legal incapacity limit legal capacity screening . 17 . Subjects vegetarian , vegan dietary restriction conflict study standardise menu .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>